Abstract Ref Number = APCP916
PROFILE AND EVALUATION OF PATIENTS TREATED WITH INDONESIAN ACUTE MYELOID LEUKEMIA PROTOCOL 2011 (REVISED 2015) IN SAIFUL ANWAR HOSPITAL
ADE HABIBI,Dian Maharani,Puji Mirantiningsih,Sony Wicaksono,Susanto Nugroho
Pediatric Departement Medical Faculty of Brawijaya University Malang East Java Indonesia Pediatric Departement Medical Faculty of Brawijaya University, Malang East Java Indonesia
Background : there are diversity in protocols for pediatric AML. We used National Protocol of Indonesian Childhood AML 2011 (Revised 2015). The evaluation of this protocol hasn’t been published yet.
Material : The aim of this study was to describe the profile and evaluate the hematological aspect of AML treated with National Protocol of Indonesian Childhood AML 2011 (Revised 2015).
Results : There were 18 patient diagnosis as AML during 2017 which consist of AML M1 (2/18), M2 (3/18), M4 (6/18), M5 (7/18). The male:female ratio was 1.25:1 with median age 7.05 years. The clinical presentation at first admission were paleness (16/18), fever (12/18), bleeding (8/18), hepatomegaly (15/18), splenomegaly (10/18), undernourshment (9/18), malnourishment (3/18). Initial laboratory result revealed median level of hemoglobin 6.95 g/dL, leukocytes 18575/µL, thrombocytes 62666/µL and absolute neutrophil counts 1309. The adverse effects of chemotherapy were nausea (10/18), vomiting (6/18), bleeding (9/18), diarrhea (3/18), febril neutropenia (10/18), anemia (15/18) and thrombocytopenia (14/18) mostly reported in the first week of chemotherapy. At second bone marrow evaluation, 3 patient had partial remission and 8 patient had total remission whom 5/8 patient relapsed. At the end of this study only 8 patient were still alive. The mean survival rate using Kaplan Mier analysis was 273,2 days. There were significantly different result in hemoglobine, leucosytes, thrombocytes before and during chemotherapy (P=0.001; P=0.01; P=0.024).
Conclusions : There is significant improvement of hemoglobin, trombocytes and decrease of leukocytes level during chemotherapy. The mean survival time was 273.2 days.
Keywords: Indonesian AML protocol 2011 (revised 2015), profile hematological evaluation